This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Merck: Investing in Science-Based Business (Abridged)
Raman, Ananth; Maurer, IngaCase HBS-611027-EService and Operations ManagementRay Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless Gilmartin cuts the R&D budget. Cutting the budget might hurt morale and productivity in Merck labs.Starting at €8.20
-
Merck: Operating Science-Based Business
Raman, Ananth; Maurer, Inga; Schmidt, WilliamCase HBS-612082-EService and Operations ManagementMerck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure?Starting at €8.20